First-generation CARs were designed similarly to the endogenous TCR complex by incorporating a CD3ζ- chain or FcεRIγ intracellular domain, but instead incorporated extracellular antigen-recognition domains that allowed for direct antigen-recognition on the surface of tumor cells, allowing for MHC-independent T cell activation (Fig. 1). This evidence concerns the gene HLA-C and neoplasm.